Kiora Pharma 
Welcome,         Profile    Billing    Logout  
 2 Products   4 Diseases  2 Products   2 Trials   40 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
KIO-101 / Kiora Pharma
NCT05629364: A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease

Terminated
2
4
RoW
KIO-101, DHODH inhibitor
Kiora Pharmaceuticals, Inc.
Dry Eye Disease
01/24
01/24
KIO-301 / Kiora Pharma
ABACUS-2, NCT06628947: A Phase II Study of Intravitreal KIO-301 in Patients with Late-stage Retinitis Pigmentosa

Not yet recruiting
2
36
NA
Placebo (Sterile Saline), 100 μg KIO-301, 50 μg KIO-301
Kiora Pharmaceuticals, Inc.
Retinitis Pigmentosa
03/26
05/26
ABACUS, NCT05282953: A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients with Retinitis Pigmentosa and Choroideremia

Recruiting
1/2
12
RoW
KIO-301
Kiora Pharmaceuticals, Inc.
Retinitis Pigmentosa, Choroideremia
06/25
09/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
KIO-101 / Kiora Pharma
NCT05629364: A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease

Terminated
2
4
RoW
KIO-101, DHODH inhibitor
Kiora Pharmaceuticals, Inc.
Dry Eye Disease
01/24
01/24
KIO-301 / Kiora Pharma
ABACUS-2, NCT06628947: A Phase II Study of Intravitreal KIO-301 in Patients with Late-stage Retinitis Pigmentosa

Not yet recruiting
2
36
NA
Placebo (Sterile Saline), 100 μg KIO-301, 50 μg KIO-301
Kiora Pharmaceuticals, Inc.
Retinitis Pigmentosa
03/26
05/26
ABACUS, NCT05282953: A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients with Retinitis Pigmentosa and Choroideremia

Recruiting
1/2
12
RoW
KIO-301
Kiora Pharmaceuticals, Inc.
Retinitis Pigmentosa, Choroideremia
06/25
09/25

Download Options